Mikael Björnstedt Selected Research

Selenious Acid (Selenite)

1/2022	Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial.
10/2020	The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines.
11/2016	Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
3/2016	Quantification of low molecular weight selenium metabolites in human plasma after treatment with selenite in pharmacological doses by LC-ICP-MS.
5/2015	Redox-active selenium compounds--from toxicity and cell death to cancer treatment.
10/2011	Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.
9/2009	Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift.
9/2009	Selenite is a potent cytotoxic agent for human primary AML cells.
7/2009	Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite.
6/2009	Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mikael Björnstedt Research Topics

Disease

31	Neoplasms (Cancer) 01/2022 - 02/2004
5	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2002
4	Liver Neoplasms (Liver Cancer) 10/2020 - 08/2005
4	Carcinoma (Carcinomatosis) 01/2019 - 01/2009
3	Hepatocellular Carcinoma (Hepatoma) 07/2021 - 04/2012
3	Malignant Mesothelioma 06/2009 - 09/2006
2	Cholangiocarcinoma 05/2022 - 10/2020
2	Sclerosing Cholangitis 05/2012 - 04/2007
2	Ovarian Neoplasms (Ovarian Cancer) 06/2011 - 01/2010
2	Mesothelioma 06/2009 - 09/2006
2	Small Cell Carcinoma 02/2004 - 05/2002
1	COVID-19 12/2022
1	Myocarditis (Carditis) 12/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2022
1	Neoplasms, Cystic, Mucinous, and Serous 05/2022
1	Reperfusion Injury 12/2017
1	Genetic Translocation (Chromosomal Translocation) 11/2016
1	Acute Promyelocytic Leukemia 11/2016
1	Alzheimer Disease (Alzheimer's Disease) 01/2014
1	Cognitive Dysfunction 01/2014
1	Cardiomyopathies (Cardiomyopathy) 09/2013
1	Ischemia 08/2011
1	Prostatic Neoplasms (Prostate Cancer) 09/2010
1	Hepatitis B 09/2010
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 09/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2009
1	Adenocarcinoma 09/2009
1	Erythropoietic Protoporphyria 01/2007
1	Liver Diseases (Liver Disease) 01/2007
1	Cholestasis 01/2007
1	Melanoma (Melanoma, Malignant) 04/2005
1	Carcinogenesis 01/2005

Drug/Important Bio-Agent (IBA)

19	SeleniumIBA 01/2022 - 05/2002
16	Selenious Acid (Selenite)IBA 01/2022 - 05/2002
7	Proteins (Proteins, Gene)FDA Link 12/2022 - 09/2009
6	Pharmaceutical PreparationsIBA 07/2021 - 05/2002
6	Selenium CompoundsIBA 10/2020 - 01/2005
5	ThioredoxinsIBA 01/2014 - 02/2004
4	AntibodiesIBA 12/2022 - 02/2007
4	Thioredoxin-Disulfide ReductaseIBA 07/2012 - 11/2004
4	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2006 - 05/2002
3	Messenger RNA (mRNA)IBA 07/2021 - 02/2007
3	Sodium SeleniteIBA 10/2020 - 06/2008
3	Thioredoxin Reductase 1IBA 05/2012 - 02/2007
2	ParaffinIBA 05/2022 - 09/2009
2	MicroRNAs (MicroRNA)IBA 07/2021 - 10/2020
2	selenomethylselenocysteine (methylselenocysteine)IBA 07/2021 - 10/2020
2	Biological ProductsIBA 01/2021 - 01/2012
2	Cytostatic AgentsIBA 10/2020 - 06/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2014 - 07/2010
2	GlutaredoxinsIBA 01/2014 - 09/2009
2	GoldIBA 07/2012 - 01/2010
2	phosphine (phosphane)IBA 07/2012 - 01/2010
2	Sulfhydryl Compounds (Thiols)IBA 10/2011 - 07/2009
2	Protein Isoforms (Isoforms)IBA 09/2009 - 02/2007
2	SaltsIBA 07/2009 - 04/2005
2	Peptides (Polypeptides)IBA 02/2007 - 11/2004
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2022
1	B7-H1 AntigenIBA 01/2022
1	InterferonsIBA 09/2021
1	Lipid NanoparticlesIBA 07/2021
1	kynurenine-oxoglutarate transaminaseIBA 07/2021
1	Folic Acid (Vitamin M)FDA LinkGeneric 06/2021
1	Folate Receptor 1IBA 06/2021
1	CytokinesIBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 11/2016
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2016
1	selenocystineIBA 05/2015
1	Acute Hepatic PorphyriaIBA 11/2013
1	coenzyme Q10 (CoQ10)IBA 09/2013
1	Cyclin D1IBA 05/2012
1	Biomarkers (Surrogate Marker)IBA 05/2012
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2012
1	Glycerol (Glycerine)FDA LinkGeneric 08/2011
1	Glucose (Dextrose)FDA LinkGeneric 08/2011
1	Pyruvic Acid (Pyruvate)IBA 08/2011
1	Lactic Acid (Lactate)FDA LinkGeneric 08/2011
1	ChalcogensIBA 06/2011
1	Selenoproteins (Selenoprotein)IBA 04/2010
1	Cisplatin (Platino)FDA LinkGeneric 01/2010
1	Auranofin (Ridaura)FDA Link 09/2009
1	tellurous acid (tellurate)IBA 09/2009
1	Cystine (L-Cystine)IBA 07/2009
1	Subfamily B ATP Binding Cassette TransporterIBA 07/2009
1	Cysteine (L-Cysteine)FDA Link 07/2009
1	AntiportersIBA 07/2009
1	Antineoplastic Agents (Antineoplastics)IBA 06/2009
1	pycnogenolsIBA 01/2009
1	AntioxidantsIBA 01/2009
1	protoporphyrin IXIBA 01/2007
1	Selenic AcidIBA 04/2005

Therapy/Procedure

4	Therapeutics 09/2021 - 02/2004
3	Immunotherapy 01/2022 - 10/2011
3	Drug Therapy (Chemotherapy) 05/2019 - 07/2009
1	Warm Ischemia 12/2017
1	Molecular Targeted Therapy 11/2016
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2007
1	Liver Transplantation 08/2005